文献速递关节外科

联邦医疗保险优势计划的兴起:对全关节置换术患者诊疗与研究的影响

The Rise of Medicare Advantage: Effects on Total Joint Arthroplasty Patient Care and Research.
PubMed 文献 · J Bone Joint Surg Am · 2022-10-26

该研究利用Premier医疗数据库分析2004至2020年接受初次全髋或全膝关节置换术的65岁以上患者,发现联邦医疗保险优势计划(MA)覆盖率从7.9%升至34.4%。2015至2020年间,MA组非白人患者比例更高,且多种术后并发症的校正比值比高于传统联邦医疗保险(TM)组。

要点

  • 2004至2020年,MA覆盖率从7.9%升至34.4%,2020年约每3例中1例为MA。
  • 2015至2020年MA组黑人患者比例8.29%高于TM组4.62%,白人患者比例84.0%低于TM组89.2%。
  • 校正混杂后,MA组手术部位感染、假体周围关节感染、卒中、急性肾损伤的比值比高于TM组。

核心结论

  • 2004至2020年MA使用显著增加,2020年约三分之一患者由MA覆盖。
  • 2015至2020年非白人患者更可能使用MA,MA组多种术后并发症发生率高于TM组。
  • TM理赔数据影响医疗政策与临床决策,此变化预示关节置换登记研究受限、外科医生行政负担增加及医疗社会差异可能恶化等未来挑战。

研究设计与样本

  • 利用Premier医疗数据库识别65岁及以上接受初次全膝或全髋关节置换术的患者,分为TM与MA队列。
  • 使用2004至2020年数据描述保险覆盖趋势,2015至2020年数据比较患者特征与术后并发症。
  • 使用2015至2020年数据进行多变量分析以控制潜在混杂因素。

主要发现

  • 2004至2020年MA比例从7.9%增至34.4%,TM比例从83.7%降至54.0%。
  • 2015至2020年共697317例初次择期全关节置换术患者,TM组471439例(67.6%),MA组225878例(32.4%)。
  • 两组年龄和性别相似,但MA组黑人患者比例8.29%高于TM组4.62%(p < 0.001),白人患者比例84.0%低于TM组89.2%(p < 0.001)。
  • 校正混杂后,MA组手术部位感染aOR 1.15(95%CI 1.04至1.47;p = 0.031)、假体周围关节感染aOR 1.10(95%CI 1.03至1.18;p = 0.006)、卒中aOR 1.15(95%CI 1.02至1.31;p = 0.026)、急性肾损伤aOR 1.08(95%CI 1.04至1.11;p < 0.001)的比值比高于TM组,尿路感染aOR 0.94(95%CI 0.90至0.98;p = 0.003)的比值比低于TM组。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Medicare Advantage (MA) plans are popular among Medicare-eligible patients, but little is known about MA in lower-extremity total joint arthroplasty (TJA). The purpose of this study was to describe trends in MA utilization and analyze differences in patient characteristics and postoperative outcomes between patients undergoing primary TJA using traditional Medicare (TM) or MA plans. METHODS: Patients ≥65 years of age who underwent primary total knee or total hip arthroplasty were identified using the Premier Healthcare Database. Patients were categorized into TM and MA cohorts. Data from 2004 to 2020 were used to describe trends in insurance coverage. Data from 2015 to 2020 were used to identify differences in patient characteristics and postoperative complications using ICD-10 codes. Multivariate analyses were performed using 2015 to 2020 data to account for potential confounders. RESULTS: From 2004 to 2020, the proportion of patients with MA increased from 7.9% to 34.4%, while those with TM decreased from 83.7% to 54.0%. Of the 697,317 patients who underwent primary elective TJA from 2015 to 2020, 471,439 (67.6%) had TM coverage and 225,878 (32.4%) had MA coverage. The cohorts were similar in terms of age and sex. However, a higher proportion of Black patients (8.29% compared with 4.62%; p < 0.001) and a lower proportion of White patients (84.0% compared with 89.2%; p < 0.001) were enrolled in MA compared with TM. After controlling for confounders, patients with MA had higher odds of surgical site infection (adjusted odds ratio [aOR]: 1.15; 95% confidence interval [CI]: 1.04 to 1.47; p = 0.031), periprosthetic joint infection (aOR: 1.10; 95% CI: 1.03 to 1.18; p = 0.006), stroke (aOR: 1.15; 95% CI: 1.02 to 1.31; p = 0.026), and acute kidney injury (aOR: 1.08; 95% CI: 1.04 to 1.11; p < 0.001), but lower odds of urinary tract infection (aOR: 0.94; 95% CI: 0.90 to 0.98; p = 0.003). CONCLUSIONS: From 2004 to 2020, the number of patients utilizing MA increased markedly such that 1 in 3 were covered by MA in 2020. From 2015 to 2020, patients who were non-White were more likely to have MA than TM, and the MA group had a higher rate of several postoperative complications compared with the TM group. As TM claims data inform health-care policy and clinical decisions, this change portends future challenges, including limitations in arthroplasty registry research, an increase in the administrative burden of surgeons, and a potential worsening of social disparities in health care.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Wang JC, Piple AS, Chen XT, et al. The Rise of Medicare Advantage: Effects on Total Joint Arthroplasty Patient Care and Research. J Bone Joint Surg Am. 2022. PMID: 36367757. doi:10.2106/JBJS.22.00254

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。